Biotron Ltd has released a press release.
Quarterly Cashflow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Biotron
- Biotron Compounds Show Activity Against SARS-CoV-2 Virus
- Full Year Statutory Accounts
- BIT225 Reverses HIV-Induced Immune Evasion
- R&D Tax Refund Received
- BIT225 restores immune function in hiv-1 infections
Later from Biotron
- Appendix 4C - quarterly
- $1.4M R&D Tax Rebate
- Full Year Statutory Accounts and Preliminary Final Report
- Quarterly Cash Flow Report
- Commencement of two pivotal BIT225 clinical trials
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron